Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration ...

ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature ...

The Mt. Sinai study could open the door to future therapies for Alzheimer’s, amyotrophic lateral sclerosis, brain cancer, and ...

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager ...

Thousands of retailers will participate with in-store MDA Shamrocks pin-ups and roundups throughout February and March; and a ...

Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological ...

Innovative lipid nanoparticles enable mRNA delivery to the brain, offering new avenues for treating neurological disorders by crossing the blood-brain barrier.

Deep within the Apple operating system are capabilities that allow users to summon apps, send emails and texts, play music ...

Nura Bio, Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies ...